1. Home
  2. PPG vs INSM Comparison

PPG vs INSM Comparison

Compare PPG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPG Industries Inc.

PPG

PPG Industries Inc.

HOLD

Current Price

$106.18

Market Cap

23.6B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$115.84

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPG
INSM
Founded
1883
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6B
22.4B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
PPG
INSM
Price
$106.18
$115.84
Analyst Decision
Buy
Strong Buy
Analyst Count
12
24
Target Price
$124.25
★ $201.17
AVG Volume (30 Days)
1.4M
★ 1.9M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
★ 2.71%
N/A
EPS Growth
★ 46.11
N/A
EPS
★ 1.70
N/A
Revenue
N/A
N/A
Revenue This Year
$4.42
$182.31
Revenue Next Year
$3.03
$65.19
P/E Ratio
$62.91
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$93.39
$90.39
52 Week High
$133.43
$212.75

Technical Indicators

Market Signals
Indicator
PPG
INSM
Relative Strength Index (RSI) 41.77 41.42
Support Level $103.71 $97.66
Resistance Level $107.99 $119.54
Average True Range (ATR) 2.01 4.76
MACD 0.34 -1.10
Stochastic Oscillator 57.81 8.29

Price Performance

Historical Comparison
PPG
INSM

About PPG PPG Industries Inc.

PPG is the world's second-largest producer of paints and coatings. PPG's products are sold to a wide variety of end users, including industrial segments such as automotive, aerospace, and protective and marine, as well as paint contractors and do-it-yourself customers. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: